

## TABLE OF CONTENTS

Sr. No.	Topic	Page No.
	<b>Contents</b>	<b>I</b>
	<b>List of Tables</b>	<b>VI</b>
	<b>List of Figures</b>	<b>XIII</b>
	<b>List of Abbreviations</b>	<b>XXIII</b>
	<b>CHAPTER 1 INTRODUCTION</b>	
1.1	Introduction	1
1.2	Aims	7
1.3	Objectives	7
1.4	Hypothesis	8
1.5	Plan of Work	8
1.6	References	9
	<b>CHAPTER 2 LITERATURE REVIEW</b>	
2.1	Oral Delivery	12
2.2	Nanotechnology	13
2.3	Lipid Based Drug Delivery Systems (LBDDS)	14
2.4	Factors Affecting Lymphatic Transport of Nanoparticles	20
2.5	Transport Mechanisms Across Intestinal Epithelium	23
2.6	Schizophrenia	26
2.7	Nanoparticles as a Drug Delivery System in Brain Delivery	27
2.8	Solid lipid nanoparticles (SLNs)	27
2.9	Self-Microemulsifying Drug Delivery System (SMEDDS)	38
2.10	Drug Profiles	52
2.11	Excipients Profile	61
2.12	References	75
	<b>CHAPTER 3 ANALYTICAL METHOD DEVELOPMENT</b>	
3.1	Introduction	87
3.2	Materials	87
3.3	Estimation of Asenapine Maleate by UV spectroscopy	87
3.4	Estimation of Asenapine Maleate using HPLC	88

3.5	HPLC method for estimation of Asenapine Maleate in plasma	89
3.6	Estimation of Lurasidone HCl by UV spectroscopy	89
3.7	Estimation of Lurasidone HCl using HPLC	91
3.8	HPLC method for estimation of Lurasidone HCl in plasma	91
3.9	Analytical method validation	92
3.10	Results and discussion	94
3.11	Conclusion	129
3.12	References	130

#### **CHAPTER 4 SOLID LIPID NANOPARTICLES OF ASENAPINE MALEATE**

4.1	Introduction	131
4.2	Materials	132
4.3	Equipment	132
4.4	Screening of solid lipid	132
4.5	Preparation of solid lipid nanoparticles	133
4.6	Experimental design	133
4.7	Lyophilization of SLNs and optimization of cryoprotectant	135
4.8	Characterization	135
4.9	In vitro drug release study	137
4.10	Ex vivo permeation study	138
4.11	Stability study	139
4.12	Results and discussion	140
4.13	Characterization	165
4.14	In vitro drug release study	174
4.15	Ex vivo permeability study	176
4.16	Stability study	176
4.17	References	178

#### **CHAPTER 5 SELF MICRORMULSIFYING DRUG DELIVERY SYSTEM OF ASENAPINE MALEATE**

5.1	Introduction	182
5.2	Materials	182
5.3	Preformulation studies	183

5.4	Formulation development	184
5.5	Optimization using D-optimal design	184
5.6	Characterization	185
5.7	In vitro drug release study	187
5.8	Ex vivo permeation study	187
5.9	Stability study	188
5.10	Results and discussion	189
5.11	Characterization	210
5.12	In vitro drug release study	215
5.13	Ex vivo permeability study	215
5.14	Stability study	216
5.15	References	218

## **CHAPTER 6 SOLID LIPID NANOPARTICLES OF LURASIDONE HCl**

6.1	Introduction	222
6.2	Materials	223
6.3	Equipment	224
6.4	Screening of solid lipid	224
6.5	Preparation of solid lipid nanoparticles	224
6.6	Experimental design	224
6.7	Lyophilization of SLNs and optimization of cryoprotectant	226
6.8	Characterization	227
6.9	In vitro drug release study	228
6.10	Ex vivo permeation study	228
6.11	Stability study	228
6.12	Results and discussion	229
6.13	Characterization	252
6.14	In vitro drug release study	262
6.15	Ex vivo permeability study	264
6.16	Stability study	265
6.17	References	266

**CHAPTER 7 SELF MICRORMULSIFYING DRUG DELIVERY SYSTEM  
OF LURASIDONE HCl**

7.1	Introduction	269
7.2	Materials	270
7.3	Preformulation studies	270
7.4	Formulation development	270
7.5	Optimization using 3 <sup>2</sup> factorial design	270
7.6	Characterization	272
7.7	In vitro drug release study	272
7.8	Ex vivo permeation study	272
7.9	Stability study	272
7.10	Results and discussion	273
7.11	Characterization	287
7.12	In vitro drug release study	292
7.13	Ex vivo permeability study	293
7.14	Stability study	294
7.15	References	295

**CHAPTER 8 CELL LINE STUDIES**

8.1	Introduction	298
8.2	Materials	299
8.3	Methods	299
8.4	Results and discussion	304
8.5	Conclusion	329
8.6	References	330

**CHAPTER 9 IN VIVO STUDY**

9.1	Introduction	334
9.2	Study protocol	334
9.3	Pharmacokinetic study	335
9.4	Intestinal lymphatic transport study in rats	336
9.5	Pharmacodynamic study	336
9.6	Results and discussion	340
9.7	Conclusion	357
9.8	References	358

## CHAPTER 10 SUMMARY AND CONCLUSIONS

10.1	Summary	363
10.2	Conclusions	373
	<b>Appendix I</b>	<b>i</b>